| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
 |
|
Site Navigation
| ALS News & Research For postings of news or research links and articles related to ALS |
advertisement
| Reply |
|
|
Thread Tools | Display Modes |
|
|
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
05-29-2024, 11:40 AM
|
#1 | |||
|
||||
|
Grand Magnate
|
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants - Full Text View - ClinicalTrials.gov SPG302 trial set to begin in Australia SPG302 trial set to begin in Australia | MND Australia Second half of phase one study in Australia beginning . . . hoping to increase synapses in motor system. |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apom | Parkinson's Disease | |||
| VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy V | ALS News & Research | |||
| ALS Therapy Development Institute Announces Resignation of CEO James Heywood and Appo | ALS News & Research | |||
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for
Linear Mode
